What is Alexza Pharmaceuticals Shares Outstanding (Basic Average)?
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Alexza Pharmaceuticals's average basic shares outstanding for the quarter that ended in Mar. 2016 was 20.81 Mil.
Alexza Pharmaceuticals Shares Outstanding (Basic Average) Historical Data
The historical data trend for Alexza Pharmaceuticals's Shares Outstanding (Basic Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Alexza Pharmaceuticals Shares Outstanding (Basic Average) Related Terms
Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXA has been successfully added to your 